HealthyPhase 1NCT05288816
A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
A Phase 1 study testing ALXN1210 in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
Trial summary
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams [mg]) of ALXN1210 following intravenous administration to healthy Japanese participants. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- ALXN1210
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 18 Apr 2016to 5 Jul 2017
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy Japanese males or females aged 25 through 55 years, inclusive (participants who lived outside of Japan for ≤ 10 years and were first-generation Japanese, defined as born in Japan and having 4 biological grandparents who were ethnic Japanese).
- Body mass index from 18 through 29.9 kilogram/square meter (kg/m^2), inclusive, with weight between 50 and 100 kg, inclusive.
- QT interval (corrected using the Fridericia's formula) ≤ 450 milliseconds (msec) for males and ≤ 470 msec for females at Screening and prior to dosing on Day 1.
- Willing and able to give written informed consent and comply with the study visit schedule
- Documented vaccination with tetravalent meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 3 years prior to dosing. Documentation included a positive serum bactericidal assay to confirm an immune response before study drug administration.
- Vaccination with serogroup B meningococcal vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1, with at least 28 days between the first and second injections.
- Female participants of childbearing potential were required to use highly effective contraception, starting at Screening and continuing until at least 6 months (Cohort 1) or 8 months (Cohorts 2 and 3) after the last dose of ALXN1210.
- Male participants with a female spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or partner had to agree to use barrier contraception during the treatment period and for at least 6 months (Cohort 1) or 8 months (Cohorts 2 and 3) after the last dose of ALXN1210.
Who cannot join
- Participants who were in intimate and prolonged contact with (defined as living under the same roof or providing personal care) people younger than 2 years of age or older than 65 years of age, or who were either immunocompromised or had one of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies (for example, those receiving eculizumab); or human immunodeficiency virus (HIV).
- Participants who were professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel may be at increased risk of meningococcal infection when accommodated in close quarters); daycare center workers; those who lived on a college or university campus; and those who planned to travel during the course of the study or have travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) 6 months prior to dosing.
- History of any Neisseria infection
- History of unexplained, recurrent infection; or infection requiring treatment with systemic antibiotics within the 90 days prior to dosing.
- HIV infection (evidenced by HIV-1 or HIV-2 antibody titer)
- Acute or chronic hepatitis B virus infection. Hepatitis B surface antigen (HBsAg) testing was required for all participants prior to enrollment. Participants with positive HBsAg were not enrolled. For participants with negative HBsAg, the following testing algorithms were required: If hepatitis B core antibody (HBcAb) was negative, the participants was eligible to enroll and If HBcAb was positive, the hepatitis B surface antibody (HBsAb) was tested. (If both HBcAb and HBsAb were positive, the participants was eligible to enroll and If HBcAb was positive and HBsAb was negative, the participants was not enrolled.)
Show all 32Show fewer
- Acute or chronic hepatitis C virus infection (evidenced by antibody titer)
- Active systemic viral or fungal infection 14 days prior to dosing.
- Positive or indeterminate QuantiFERON-TB test indicating possible tuberculosis infection.
- History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to the Screening Visit.
- Female participants who were breastfeeding or were unwilling to practice contraception and were not postmenopausal.
- Positive serum pregnancy test at Screening or Day -1.
- Serum creatinine greater than the upper limit of normal (ULN) of the reference range of the testing laboratory at Screening or Day -1.
- Alanine aminotransferase or aspartate aminotransferase > ULN of the reference range of the testing laboratory at Screening or > 1.5*ULN of the reference range of the testing laboratory at Day -1.
- Any of the following hematology results: hemoglobin < 130 grams (g)/L for males and < 115 g/L for females; hematocrit < 0.37 L/L for males and < 0.33 L/L for females; white blood cells < 3.0*10^3/microliter (μL); absolute neutrophils < 2.0*10^3/μL; and platelets < 150 or > 400*10^3/μL at Screening or Day -1; or complete blood count clinical laboratory results that were considered clinically relevant and unacceptable by the investigator at Day -1.
- History of complement deficiency or complement activity below normal reference range as evaluated by complement alternative pathway enzyme-linked immunosorbent assay at Screening.
- History of malignancy with the exception of a nonmelanoma skin cancer or carcinoma in situ of the cervix that had been treated with no evidence of recurrence.
- Participated in a clinical study within 30 days before initiation of dosing on Day 1 or use of any experimental small-molecule therapy within 30 days prior to dosing on Day 1.
- Participated in more than 1 clinical study of a monoclonal antibody (mAb), or participation in a clinical study of an mAb within the 12 months prior to Screening, during which the participants was exposed to the active study drug. Participants who participated in only 1 study of an mAb could have been considered for enrollment if they completed that study more than 12 months prior to Screening.
- Major surgery or hospitalization within 90 days prior to dosing.
- Contraindication to receiving MCV4 and/or serogroup B vaccine, including severe allergic reaction to a previous dose of MCV4 and/or serogroup B vaccine; severe allergy to any vaccine component; or previous diagnosis of Guillain-Barré syndrome.
- History of allergy to excipients of ALXN1210 (for example, polysorbate 80)
- Documented history of penicillin or cephalosporin
- History of significant allergic reaction (anaphylaxis, or angioedema) to any product (for example, food and pharmaceutical).
- Smoked > 10 cigarettes daily (former smokers may have been permitted to enroll at the Investigator's discretion)
- Positive urine drug toxicology screen at Screening or Day -1.
- Donated plasma within 7 days prior to dosing. Donated or lost more than 50 mL of blood within 30 days of dosing or lost more than 499 mL of blood within 56 days of dosing
- Used prescription medications within 14 days prior to study drug administration.
- Clinical diagnosis of any autoimmune or rheumatologic disease.
- Immunized with a live-attenuated vaccine 1 month prior to dosing or planned vaccination during the course of the study (except for the vaccination planned by the study protocol). Immunization with inactivated or recombinant influenza vaccine was permitted.
- Had fever (confirmed body temperature > 37.6°C) (for example, a fever associated with a symptomatic viral or bacterial infection) within 14 days prior to the first dosing.
- Participants with any medical history, conditions or risks which, in the opinion of the Investigator, may have interfered with the participant's full participation in the study, or compliance with the protocol, or posed any additional risk for the participant, or confounded the assessment of the participant or outcome of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1, Open-Label, Single Ascending and Multiple Set Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Japanese Subjects
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams [mg]) of ALXN1210 following intravenous administration to healthy Japanese participants.
Read the detailed description
A total of 3 cohorts were enrolled sequentially. Participants received different doses per Cohorts: Cohort 1, 400 mg single dose; Cohort 2, 800 mg single dose; and Cohort 3, 800 mg every 4 weeks for a total of 5 doses. The Safety Review Committee (SRC) conducted a review of the available clinical and safety data after the last participants in the 400 mg cohort (Cohort 1) completed Day 15 to determine if dose escalation to the single dose 800 mg (Cohort 2) could proceed. The SRC then conducted a review of all available clinical and safety data after the last participants in Cohort 2 completed Day 15 to determine if dosing of Cohort 3 could begin. A 120-day (Cohort 1) or 140-day (Cohort 2) Follow-up Period was performed for safety, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity assessments. Participants in Cohort 3, however, had a 185-day Follow-up Period for safety, PK, PD, and immunogenicity assessments after the fifth dose of study drug.
- Conditions
- Healthy
- Being tested
- ALXN1210
- Keywords
- ALXN1210, Pharmacokinetics, Pharmacodynamics, Safety, Immunogenicity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALXN1210Drug
Also called Ultomiris, Ravulizumab
Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: ALXN1210 400 mg (Single) | Experimental | A single dose of ALXN1210 was administered intravenously. Receives: Drug: ALXN1210 |
| Cohort 2: ALXN1210 800 mg (Single) | Experimental | A single dose of ALXN1210 was administered intravenously. Receives: Drug: ALXN1210 |
| Cohort 3: ALXN1210 800 mg (Multiple) | Experimental | ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses. Receives: Drug: ALXN1210 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Measured: Cohort 1: Baseline up to Day 120; Cohort 2: Baseline up to Day 140; Cohort 3: Baseline up to Day 298
Secondary outcomes (11)
Number of Participants With Anti-Drug Antibodies (ADAs) To ALXN1210
Blood samples were collected to evaluate antibody response through development of ADAs.
Measured: Cohort 1: Baseline up to Day 120; Cohort 2: Baseline up to Day 140; Cohort 3: Baseline up to Day 298
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) For Single Dose of ALXN1210
Blood samples were collected for estimation of AUCinf using Phoenix WinNonlin software version 7.0.
Measured: Cohort 1: Baseline (pre-dose) up to Day 120; Cohort 2: Baseline (pre-dose) up to Day 140
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) For Multiple Dose of ALXN1210
Blood samples were collected for estimation of AUCinf using Phoenix WinNonlin software version 7.0.
Measured: Day 113 (pre-dose) up to Day 298
Maximum Observed Serum Concentration (Cmax) For Single Dose of ALXN1210
Blood samples were collected for estimation of Cmax using Phoenix WinNonlin software version 7.0.
Measured: Cohort 1: Baseline (pre-dose) up to Day 120; Cohort 2: Baseline (pre-dose) up to Day 140
Maximum Observed Serum Concentration (Cmax) For Multiple Dose of ALXN1210
Blood samples were collected for estimation of Cmax using Phoenix WinNonlin software version 7.0.
Measured: Day 113 (pre-dose) up to Day 298
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 1
Measured: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113
Measured: Baseline, Day 113 (end of infusion)
Percent Change From Baseline in Total C5 Concentration at Day 1
Measured: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Total C5 Concentration at Day 113
Measured: Baseline, Day 113 (end of infusion)
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 1
Measured: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113
Measured: Baseline, Day 113 (end of infusion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2022
- Study start18 Apr 2016
- Primary completion5 Jul 2017
- Study completion5 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Alexion Pharmaceuticals, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05288816
- Sponsor's protocol ID
- ALXN1210-HV-104
- Other IDs
- 2015-005468-40, 2015
- Status last verified
- May 2023
- First submitted
- 11 Mar 2022
- Last updated
- 5 Feb 2024
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open-Label, Single Ascending and Multiple Set Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Japanese Subjects
- ClinicalTrials.gov ID
- NCT05288816
- Acronym / sponsor ID
- ALXN1210-HV-104
- Conditions
- Healthy
- Keywords
- ALXN1210, Pharmacokinetics, Pharmacodynamics, Safety, Immunogenicity
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 18 Apr 2016 (actual)
- Primary completion
- 5 Jul 2017 (actual)
- Study completion
- 5 Jul 2017 (actual)
- First posted
- 21 Mar 2022 (actual)
- Results
- Posted 5 Feb 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams [mg]) of ALXN1210 following intravenous administration to healthy Japanese participants.
Detailed description
A total of 3 cohorts were enrolled sequentially. Participants received different doses per Cohorts: Cohort 1, 400 mg single dose; Cohort 2, 800 mg single dose; and Cohort 3, 800 mg every 4 weeks for a total of 5 doses. The Safety Review Committee (SRC) conducted a review of the available clinical and safety data after the last participants in the 400 mg cohort (Cohort 1) completed Day 15 to determine if dose escalation to the single dose 800 mg (Cohort 2) could proceed. The SRC then conducted a review of all available clinical and safety data after the last participants in Cohort 2 completed Day 15 to determine if dosing of Cohort 3 could begin. A 120-day (Cohort 1) or 140-day (Cohort 2) Follow-up Period was performed for safety, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity assessments. Participants in Cohort 3, however, had a 185-day Follow-up Period for safety, PK, PD, and immunogenicity assessments after the fifth dose of study drug.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: ALXN1210 400 mg (Single) | Experimental | Drug: ALXN1210A single dose of ALXN1210 was administered intravenously. |
| Cohort 2: ALXN1210 800 mg (Single) | Experimental | Drug: ALXN1210A single dose of ALXN1210 was administered intravenously. |
| Cohort 3: ALXN1210 800 mg (Multiple) | Experimental | Drug: ALXN1210ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses. |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Healthy Japanese males or females aged 25 through 55 years, inclusive (participants who lived outside of Japan for ≤ 10 years and were first-generation Japanese, defined as born in Japan and having 4 biological grandparents who were ethnic Japanese).
- Body mass index from 18 through 29.9 kilogram/square meter (kg/m^2), inclusive, with weight between 50 and 100 kg, inclusive.
- QT interval (corrected using the Fridericia's formula) ≤ 450 milliseconds (msec) for males and ≤ 470 msec for females at Screening and prior to dosing on Day 1.
- Willing and able to give written informed consent and comply with the study visit schedule
- Documented vaccination with tetravalent meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 3 years prior to dosing. Documentation included a positive serum bactericidal assay to confirm an immune response before study drug administration.
Key exclusion criteria (32 listed)
- Participants who were in intimate and prolonged contact with (defined as living under the same roof or providing personal care) people younger than 2 years of age or older than 65 years of age, or who were either immunocompromised or had one of the following underlying medical conditions: anatomic or functional asplenia (including sickle cell disease); congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies (for example, those receiving eculizumab); or human immunodeficiency virus (HIV).
- Participants who were professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel may be at increased risk of meningococcal infection when accommodated in close quarters); daycare center workers; those who lived on a college or university campus; and those who planned to travel during the course of the study or have travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) 6 months prior to dosing.
- History of any Neisseria infection
- History of unexplained, recurrent infection; or infection requiring treatment with systemic antibiotics within the 90 days prior to dosing.
- HIV infection (evidenced by HIV-1 or HIV-2 antibody titer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALXN1210Also: Ultomiris, RavulizumabParticipants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210. | Drug | Cohort 1: ALXN1210 400 mg (Single), Cohort 2: ALXN1210 800 mg (Single), Cohort 3: ALXN1210 800 mg (Multiple) |
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Cohort 1: Baseline up to Day 120; Cohort 2: Baseline up to Day 140; Cohort 3: Baseline up to Day 298
An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
11 secondary outcomes
Number of Participants With Anti-Drug Antibodies (ADAs) To ALXN1210
Time frame: Cohort 1: Baseline up to Day 120; Cohort 2: Baseline up to Day 140; Cohort 3: Baseline up to Day 298
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) For Single Dose of ALXN1210
Time frame: Cohort 1: Baseline (pre-dose) up to Day 120; Cohort 2: Baseline (pre-dose) up to Day 140
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) For Multiple Dose of ALXN1210
Time frame: Day 113 (pre-dose) up to Day 298
Maximum Observed Serum Concentration (Cmax) For Single Dose of ALXN1210
Time frame: Cohort 1: Baseline (pre-dose) up to Day 120; Cohort 2: Baseline (pre-dose) up to Day 140
Maximum Observed Serum Concentration (Cmax) For Multiple Dose of ALXN1210
Time frame: Day 113 (pre-dose) up to Day 298
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 1
Time frame: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113
Time frame: Baseline, Day 113 (end of infusion)
Percent Change From Baseline in Total C5 Concentration at Day 1
Time frame: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Total C5 Concentration at Day 113
Time frame: Baseline, Day 113 (end of infusion)
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 1
Time frame: Baseline, Day 1 (end of infusion)
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113
Time frame: Baseline, Day 113 (end of infusion)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ALXN1210 in people with Healthy, run by Alexion Pharmaceuticals, Inc. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Feb 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment Emergent Adverse Events (TEAEs) (time frame: Cohort 1: Baseline up to Day 120; Cohort 2: Baseline up to Day 140; Cohort 3: Baseline up to Day 298). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2024.